Janne Beathe Kjersem

  • Former PhD student; MD, PhD
 

Original articles

Kjersem JB, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit KM, Wettergren Y, Kure EH (2015)
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
Pharmacogenomics J, 16 (3), 272-9
DOI 10.1038/tpj.2015.54, PubMed 26261061

Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH (2014)
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
BMC Cancer, 14, 340
DOI 10.1186/1471-2407-14-340, PubMed 24884501

Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH (2013)
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
Mol Oncol, 8 (1), 59-67
DOI 10.1016/j.molonc.2013.09.001, PubMed 24119443

Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH (2012)
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
BMC Cancer, 12, 534
DOI 10.1186/1471-2407-12-534, PubMed 23167843

Other articles

Kjersem JB (2016)
[Not Available]
Tidsskr Nor Laegeforen, 136 (7), 647
DOI 10.4045/tidsskr.16.0180, PubMed 27094673

Page visits: 5640